These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36904112)

  • 1. TM6SF2-rs58542926 Genetic Variant Modifies the Protective Effect of a "Prudent" Dietary Pattern on Serum Triglyceride Levels.
    Kalafati IP; Dimitriou M; Revenas K; Kokkinos A; Deloukas P; Dedoussis GV
    Nutrients; 2023 Feb; 15(5):. PubMed ID: 36904112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
    Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
    J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.
    Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
    Gene; 2022 Apr; 820():146235. PubMed ID: 35143946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of
    Elmansoury N; Megahed AA; Kamal A; El-Nikhely N; Labane M; Abdelmageed M; Daly AK; Wahid A
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation between PNPLA3 rs738409 and TM6SF2 rs58542926 gene polymorphism and primary liver cancer in the Han Population of China's Northeast region].
    Bing H; Wang W; Li YL
    Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):156-162. PubMed ID: 33685085
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children.
    Lin YC; Chang PF; Chang MH; Ni YH
    Liver Int; 2018 Jul; 38(7):1300-1307. PubMed ID: 29314568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
    Stickel F; Buch S; Nischalke HD; Weiss KH; Gotthardt D; Fischer J; Rosendahl J; Marot A; Elamly M; Casper M; Lammert F; McQuillin A; Zopf S; Spengler U; Marhenke S; Kirstein MM; Vogel A; Eyer F; von Felden J; Wege H; Buch T; Schafmayer C; Braun F; Deltenre P; Berg T; Morgan MY; Hampe J
    Am J Gastroenterol; 2018 Oct; 113(10):1475-1483. PubMed ID: 29535416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fish intake interacts with TM6SF2 gene variant to affect NAFLD risk: results of a case-control study.
    Kalafati IP; Dimitriou M; Borsa D; Vlachogiannakos J; Revenas K; Kokkinos A; Ladas SD; Dedoussis GV
    Eur J Nutr; 2019 Jun; 58(4):1463-1473. PubMed ID: 29574608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy.
    Di Costanzo A; Belardinilli F; Bailetti D; Sponziello M; D'Erasmo L; Polimeni L; Baratta F; Pastori D; Ceci F; Montali A; Girelli G; De Masi B; Angeloni A; Giannini G; Del Ben M; Angelico F; Arca M
    Sci Rep; 2018 Feb; 8(1):3702. PubMed ID: 29487372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome but not genetic polymorphisms known to induce NAFLD predicts increased total mortality in subjects with NAFLD (OPERA study).
    Käräjämäki AJ; Hukkanen J; Kauma H; Kesäniemi YA; Ukkola O
    Scand J Clin Lab Invest; 2020; 80(2):106-113. PubMed ID: 31851849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NAFLD-related gene polymorphisms and all-cause and cause-specific mortality in an Asian population: the Shanghai Changfeng Study.
    Xia M; Ma S; Huang Q; Zeng H; Ge J; Xu W; Wu Q; Wu L; Li X; Ma H; Chen L; Li Q; Aleteng Q; Hu Y; He W; Pan B; Lin H; Zheng Y; Wang S; Tang H; Gao X
    Aliment Pharmacol Ther; 2022 Mar; 55(6):705-721. PubMed ID: 35023183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China.
    Liao S; An K; Liu Z; He H; An Z; Su Q; Li S
    J Clin Lab Anal; 2022 Sep; 36(9):e24626. PubMed ID: 35881683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.
    Koo BK; Joo SK; Kim D; Bae JM; Park JH; Kim JH; Kim W
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1277-1285. PubMed ID: 29193269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C.
    Petta S; Maida M; Grimaudo S; Pipitone RM; Macaluso FS; Cabibi D; Cammà C; Di Marco V; Sferrazza S; Craxì A
    Liver Int; 2016 Feb; 36(2):198-204. PubMed ID: 26259026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.
    Sookoian S; Castaño GO; Scian R; Mallardi P; Fernández Gianotti T; Burgueño AL; San Martino J; Pirola CJ
    Hepatology; 2015 Feb; 61(2):515-25. PubMed ID: 25302781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
    Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
    Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
    Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
    J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects.
    Sliz E; Sebert S; Würtz P; Kangas AJ; Soininen P; Lehtimäki T; Kähönen M; Viikari J; Männikkö M; Ala-Korpela M; Raitakari OT; Kettunen J
    Hum Mol Genet; 2018 Jun; 27(12):2214-2223. PubMed ID: 29648650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of the association between MBOAT7 rs641738, TM6SF2 rs58542926 and nonalcoholic fatty liver disease susceptibility.
    Xia Y; Huang CX; Li GY; Chen KH; Han L; Tang L; Luo HQ; Bao MH
    Clin Res Hepatol Gastroenterol; 2019 Oct; 43(5):533-541. PubMed ID: 30824369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models.
    Longo M; Meroni M; Paolini E; Erconi V; Carli F; Fortunato F; Ronchi D; Piciotti R; Sabatini S; Macchi C; Alisi A; Miele L; Soardo G; Comi GP; Valenti L; Ruscica M; Fracanzani AL; Gastaldelli A; Dongiovanni P
    Cell Mol Gastroenterol Hepatol; 2022; 13(3):759-788. PubMed ID: 34823063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.